Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

NCT02625961 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

296

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Pembrolizumab/vibostolimab coformulation
BIOLOGICAL: Favezelimab/pembrolizumab coformulation

Sponsor

Merck Sharp & Dohme LLC